Hosted on MSN2h
Keymed’s Stapokibart approved by NMPA for seasonal allergic rhinitis
China's National Medical Products Administration (NMPA) has approved Keymed Biosciences’ supplemental new drug application ...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...
emjreviews.com3d
NICE Endorses First-of-Its-Kind Allergic Rhinitis Treatment
Discover how a newly recommended immunotherapy works by gradually increasing the body’s resistance to house dust mites.
Medscape6d
Combination Nasal Steroid–Antihistamine Is More Effective Than Either Agent Alone
For patients with allergic rhinitis, twice-daily azelastine plus ... all treatments were administered as one spray twice daily to preserve blinding. The studies were sponsored by a company that ...
The Daily Star16d
Breathe easy: The best allergy treatments
Nasal steroids provided the most significant benefit, especially when compared to montelukast. Nasal antihistamines also performed better than oral antihistamines, making sprays the top choice for ...
Drug Store News5d
Lupin receives FDA nod for generic Atrovent
Ipratropium bromide nasal solution 0.06% is indicated for symptomatic relief of rhinorrhea associated with the common cold or ...
pulmonologyadvisor6d
Rhinoconjunctivitis in Children With Asthma May Not Always Be Allergy Driven
Phenotyping children with asthma based on rhinoconjunctivitis symptoms shows that rhinoconjunctivitis may not always be allergy driven.
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ...
Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis
Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...